All News
Filter News
Found 796,712 articles
-
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
1/3/2024
Zura Bio Limited announced that members of its senior management team will present at two upcoming conferences in January.
-
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
iTeos Therapeutics, Inc. announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 10, 2024 at 3:00 p.m. PST.
-
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
1/3/2024
BioCardia completed 2023 with three active clinical programs of its autologous and allogeneic cell therapies to treat heart disease, with a focus on ischemic heart failure of reduced ejection fraction.
-
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
1/3/2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts.
-
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
1/3/2024
UCB, a global biopharmaceutical company, announced today that ZILBRYSQ® (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
-
Enovis Completes Acquisition of LimaCorporate S.p.A
1/3/2024
Enovis™ Corporation an innovation-driven, medical technology growth company, announced that it closed the acquisition of LimaCorporate S.p.A., a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.
-
Microbix Achieves Further QAPs Sales RecordOver C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency
1/3/2024
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it has sold and shipped over one million Canadian Dollars of its quality assessment products to a leading agency that provides clinical laboratory accreditation services.
-
NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors
1/3/2024
NuView Life Sciences, Inc. announced the appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to its board of directors.
-
Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer
1/3/2024
Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D.
-
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
1/3/2024
Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment received in prior LYBALVI studies.
-
Alzheon CEO Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation for Significant Contribution Towards Research and Treatment of Alzheimer’s Disease, and Donated Cash Prize to INDRC Institute
1/3/2024
Alzheon, Inc. announced that its Founder, President & CEO Dr. Martin Tolar has been awarded the Eliška and Zdeněk Strmiska Award from the Alzheimer’s Foundation for significant contribution towards the research and treatment of Alzheimer’s disease.
-
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
1/3/2024
Scribe Therapeutics Inc. announced that Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics.
-
Matinas BioPharma to Present at Biotech Showcase 2024
1/3/2024
Matinas BioPharma announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the Biotech Showcase 2024 on Tuesday, January 9, 2024 at 11:00 a.m. Pacific time.
-
Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
1/3/2024
Upstream Bio today announced the dosing of the first patients in a Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
-
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
1/3/2024
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
-
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.
-
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Voyager Therapeutics, Inc. announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024, at 9:45 a.m. PT.
-
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
1/3/2024
InspireMD announced the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
-
Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer
1/3/2024
Star Therapeutics today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.
-
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
1/3/2024
ReCode Therapeutics today announced that a patient was treated with RCT1100, a novel mRNA-based therapy currently being evaluated in a Phase 1 study in patients with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.